Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCTA02A
- Development stage
- Phase 1
- Lead developer
- Sinocelltech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
SCTA02A is a recombinant anti-HBsAg (Hepatitis B surface antigen) monoclonal antibody developed by Sinocelltech (specifically its subsidiary Shenzhou Cell Engineering). It is designed as the first clinical-stage candidate in Sinocelltech's product portfolio aimed at achieving a functional cure for chronic hepatitis B virus (HBV) infection. SCTA02A works by binding to HBsAg, neutralizing the virus, and facilitating the clearance of viral particles. It is currently being evaluated in a Phase Ia/Ib clinical trial to assess its safety, tolerability, and pharmacokinetic profile in healthy adults and patients with chronic hepatitis B.
- Other names
- recombinant anti-HBsAg monoclonal antibody重组抗HBsAg单克隆抗体注射液
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on SCTA02A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCTA02A.